| 1. |
- Haukka, Jari, et al.
(author)
-
The Impact of Forced Migration on Mortality A Cohort Study of 242,075 Finns from 1939-2010
- 2017
-
In: Epidemiology. - 1044-3983 .- 1531-5487. ; 28:4, s. 587-593
-
Journal article (peer-reviewed)abstract
- Background: The stresses and life changes associated with migration may have harmful long-term health effects, especially for mental health. These effects are exceedingly difficult to establish, because migrants are typically a highly selected group.Methods: We examined the impact of migration on health using naturally occurring historical events. In this article, we use the forced migration of 11% of the Finnish population after WWII as such a natural experiment. We observed the date and cause of death starting from 1 January 1971 and ending in 31 December 2010 for the cohort of 242,075 people. Data were obtained by linking individual-level data from the 1950 and 1970 population censuses and the register of death certificates from 1971 to 2010 (10% random sample). All-cause and cause-specific mortalities were modeled using Poisson regression.Results: Models with full adjustment for background variables showed that both all-cause mortality (RR 1.03, 95% CI 1.01, 1.05), and ischemic heart disease mortality (RR 1.11, 95% CI 1.08, 1.15) were higher in the displaced population than in the nondisplaced population. Suicide mortality was lower (RR 0.77, 95% CI 0.64, 0.92) in displaced than in the general population.Conclusions: In our long-term follow-up study, forced migration was associated with increased risk of death due to ischemic heart diseases. In contrast, lower suicide mortality was observed in association with forced migration 25 years or more.
|
|
| 2. |
- Korhonen, Pasi, et al.
(author)
-
Entacapone and prostate cancer risk in patients with Parkinson's disease
- 2015
-
In: Movement Disorders. - Hoboken, USA : Wiley-Blackwell. - 0885-3185 .- 1531-8257. ; 30:5, s. 724-728
-
Journal article (peer-reviewed)abstract
- Background: The association between Parkinson’s disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol-O-methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.Methods: We performed a retrospective cohort study using population-wide health care registers with patientlevel linkage. Prostate cancer incidence and mortality were modeled by Cox’s proportional hazards models.Results and Conclusions: Use of entacapone with Ldopa/dopa decarboxylase inhibitor caused no increased risk of prostate cancer incidence (hazard ratio [HR]: 1.05; 95% confidence interval: 0.76-1.44) or mortality (0.93; 0.43-1.98). The HR for cumulative entacapone use of >360 days versus never-use was 0.82 (0.56-1.18) for prostate cancer incidence and 1.27 (0.60-2.72) for prostate cancer mortality.
|
|
